CIK 0001661059 · Non-accelerated filer<br>Smaller reporting company
NextCure, Inc.
Sign in to watch- Ticker
- NXTC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475231247
- Phone
- 240-399-4900
- Business address
- 2850 QUARRY LAKE DRIVE, SUITE 280, BALTIMORE, MD, 21209
- Open-market buys, last 90 days
- $77,590
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$77,590. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-05-13 | CANAAN X L.P. 10% owner | Conversion | +743,110 | 1,188,976 | ||
| 2019-05-13 | CANAAN X L.P. 10% owner | Conversion | +729,599 | 1,918,575 | ||
| 2019-05-13 | CANAAN X L.P. 10% owner | Conversion | +285,867 | 2,204,442 | ||
| 2019-05-13 | CANAAN X L.P. 10% owner | Purchase | +50,000 | $15.00 | $750K | 2,254,442 |
| 2019-05-13 | CANAAN X L.P. 10% owner | Conversion · Series A-1 Preferred Stock | −3,582,000 | 0 | ||
| 2019-05-13 | CANAAN X L.P. 10% owner | Conversion · Series A-2 Preferred Stock | −5,970,000 | 0 | ||
| 2019-05-13 | CANAAN X L.P. 10% owner | Conversion · Series A-3 Preferred Stock | −5,861,455 | 0 | ||
| 2019-05-13 | CANAAN X L.P. 10% owner | Conversion · Series B-1 Preferred Stock | −2,296,605 | 0 | ||
| 2019-05-13 | ORBIMED ADVISORS LLC Director | Conversion | +445,866 | 445,866 | ||
| 2019-05-13 | ORBIMED ADVISORS LLC Director | Conversion | +743,110 | 1,188,976 | ||
| 2019-05-13 | ORBIMED ADVISORS LLC Director | Conversion | +729,599 | 1,918,575 | ||
| 2019-05-13 | ORBIMED ADVISORS LLC Director | Conversion | +442,438 | 2,361,013 | ||
| 2019-05-13 | ORBIMED ADVISORS LLC Director | Purchase | +350,000 | $15.00 | $5.3M | 2,711,013 |
| 2019-05-13 | ORBIMED ADVISORS LLC Director | Conversion · Series A-1 Preferred Stock | −3,582,000 | 0 | ||
| 2019-05-13 | ORBIMED ADVISORS LLC Director | Conversion · Series A-2 Preferred Stock | −5,970,000 | 0 | ||
| 2019-05-13 | ORBIMED ADVISORS LLC Director | Conversion · Series A-3 Preferred Stock | −5,861,455 | 0 | ||
| 2019-05-13 | ORBIMED ADVISORS LLC Director | Conversion · Series B-1 Preferred Stock | −3,554,466 | 0 |
Page 10 of 10 · 197 trades